HIGHLIGHTS
- What: The aim of this article is to review the processes driving TKIs resistance and the developments in related research.
- Who: Cancer, and Yi, Lyu from the Department of pharmacy, Shihezi University, Xinjiang, China have published the paper: The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer, in the : Proceedings of ICBioMed 2024 Workshop: Computational Proteomics in Drug Discovery and Development from Medicinal Plants of /2024/
- How: The results showed that using Afatinib as the initial treatment for rare or complex EGFR mutation-positive advanced NSCLC was superior to platinum-based . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.